TY - JOUR T1 - The impact of darbepoietin alfa in early post-transplant anaemia management: retrospective exploratory study JO - Nefrología (English Edition) T2 - AU - Jiménez,Carlos AU - González,Esther AU - Marqués,María AU - Galeano,Cristina AU - Andrés,Amado AU - Calvo,Natividad AU - Pascual,Julio SN - 20132514 M3 - 10.3265/Nefrologia.pre2012.Oct.11473 DO - 10.3265/Nefrologia.pre2012.Oct.11473 UR - https://www.revistanefrologia.com/en-the-impact-darbepoietin-alfa-in-articulo-X2013251413002606 AB - Background and objectives: The use of darbepoetin alfa in the first week of post-renal transplant (RT). Methods: Retrospective observational study carried out in four hospitals, which included all adult patients that underwent RT for 9 months with haemoglobin data during the first 6 months of post-transplant (n=129). Darbepoetin alfa was administered in accordance with the clinical practice. Results: Darbepoetin alfa was administered in the first week to 60 individuals (46.5%), who had a mean baseline Hb (±standard deviation) of 12.7g/dl±1.6g/dl. Anaemia incidence (Hb<11g/dl) during the first month was higher in patients who did not receive darbepoetin alfa (40.6% vs. 25.0% in patients treated with darbepoetin alfa, P=.045). No anaemia incidence differences were observed during months +2 to +6. There was a tendency towards transfusion decrease in patients who received darbepoetin alfa (13.3% vs. 20.3%, P=.295). Renal recovery time was similar but in the subgroup which received grafts from donors with asystole there was a tendency towards a faster recovery with darbepoetin alfa (15.1±7.7 vs. 20.1±8.8 days, P=.157). The creatinine clearance rate at 3 and 6 months was similar. Fourteen patients (10.9%) suffered from cardiovascular events with no relation to darbepoetin alfa (P=.772). Conclusions: Administering darbepoetin alfa in the first week following renal transplant reduces anaemia incidence during the first month without increase cardiovascular events. ER -